ARCHIVES

Mendelsohn Defends ImClone’s Actions And His Role In Development of C225

This article is from The Cancer Letter archive.

Vol. 28 No. 38 | October 18, 2002

Download PDF Visit The Full Archive

Related Articles

October issue of Business & Regulatory Report (8-page issue).

November 2, 2002

Centers May Become More specialized, Klausner Tells AACI

April 26, 1996

FDA Approves New Drug for Advanced Kidney Cancer

May 25, 2007

Clinical Instigator Object To HEW Proposal On Compensation Notification In Consent Forms

December 15, 1978

Phase III Lung and Pancreatic Cancer Trials Are Stopped

April 30, 2010

Also in this 8-page issue: FDA begins search for director of new Office of Oncology Drug Products.

October 8, 2004